{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:16:14Z","timestamp":1792001774669,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.tjpad.2025.100163","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T15:27:31Z","timestamp":1744990051000},"page":"100163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU\/US CTAD Task Force"],"prefix":"10.1016","volume":"12","author":[{"given":"D.","family":"Angioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-3723","authenticated-orcid":false,"given":"L.","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2896-5838","authenticated-orcid":false,"given":"P.","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9561-1872","authenticated-orcid":false,"given":"I.","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4096-6390","authenticated-orcid":false,"given":"R.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Fillit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-0942","authenticated-orcid":false,"given":"S.","family":"Salloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tjpad.2025.100163_bib0001","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/nmt-2022-0037","article-title":"The amyloid-\u03b2 pathway in Alzheimer's disease: a plain language summary","volume":"13","author":"Hampel","year":"2023","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100163_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100163_bib0003","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100163_bib0004","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.14283\/jpad.2024.112","article-title":"Clinical meaningfulness in Alzheimer's Disease Clinical trials. A report from the EU-US CTAD Task Force","volume":"11","author":"Angioni","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100163_bib0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer's disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.tjpad.2025.100163_bib0006","article-title":"Key considerations for Combination Therapy in Alzheimer's clinical trials: perspectives from an expert advisory board convened by the Alzheimer's Drug Discovery fundation","author":"Cummings","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100163_bib0007","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40263-024-01103-1","article-title":"Alzheimer's Disease: combination therapies and clinical trials for combination therapy development","volume":"38","author":"Cummings","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.tjpad.2025.100163_bib0008","unstructured":"Code of federal regulation. 3.2 Available at https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-A\/part-3\/subpart-A\/section-3.2, Accessed on Nov 20, 2024."},{"key":"10.1016\/j.tjpad.2025.100163_bib0009","unstructured":"Questions & Answers for applicants, marketing authorization holders of medicinal products and notified bodies with respect to the implementation of the Regulations on medical devices and in vitro diagnostic medical devices (Regulations (EU) 2017\/745 and (EU) 2017\/746). Available at https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/questions-answers-implementation-medical-devices-vitro-diagnostic-medical-devices-regulations-eu-2017-745-eu-2017-746_en.pdf, Accessed on Mar 24, 2025."},{"key":"10.1016\/j.tjpad.2025.100163_bib0010","unstructured":"Guideline on the Clinical Development of Fixed Combination Medicinal Products. Available at https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-development-fixed-combination-medicinal-products-revision-2_en.pdf, Accessed on March 24, 2025."},{"key":"10.1016\/j.tjpad.2025.100163_bib0011","unstructured":"Code of federal regulation. Fixed-combination prescription drugs for humans. Available at https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-D\/part-300\/subpart-B\/section-300.50, Accessed on Nov 20, 2024."},{"key":"10.1016\/j.tjpad.2025.100163_bib0012","unstructured":"Codevelopment of Two or More New Investigational Drugs for Use in Combination. Available at https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/codevelopment-two-or-more-new-investigational-drugs-use-combination, Accessed on Nov 20, 2024."},{"issue":"2","key":"10.1016\/j.tjpad.2025.100163_bib0013","article-title":"Alzheimer's disease drug development pipeline: 2024","volume":"10","author":"Cummings","year":"2024","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100163_bib0014","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13195-023-01355-x","article-title":"A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol","volume":"16","author":"Barbera","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100163_bib0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN-TU Next Generation Alzheimer's prevention trial: adaptive design and disease progression model","volume":"13","author":"Bateman","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100163_bib0016","unstructured":"Study 103 Results. https:\/\/www.eisai.com\/news\/2024\/news202480.html, Accessed on Nov 28, 2024."},{"issue":"8","key":"10.1016\/j.tjpad.2025.100163_bib0017","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","article-title":"CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease","volume":"29","author":"Horie","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.tjpad.2025.100163_bib0018","unstructured":"The Alzheimer's Disease Tau Platform Clinical Trial. https:\/\/reporter.nih.gov\/project-details\/10655872 , Accessed on Nov 28, 2024."},{"key":"10.1016\/j.tjpad.2025.100163_bib0019","unstructured":"S. Sturm et al. Oral Communication 31. 16th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24\u201327, 2023."},{"issue":"4","key":"10.1016\/j.tjpad.2025.100163_bib0020","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.tjpad.2025.100163_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-12679-1_1","article-title":"Neuroanatomy and pathology of sporadic Alzheimer's disease","volume":"215","author":"Braak","year":"2015","journal-title":"Adv Anat Embryol Cell Biol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100163_bib0022","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/alz.12192","article-title":"Hypothesis: tau pathology is an initiating factor in sporadic Alzheimer's disease","volume":"17","author":"Arnsten","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100163_bib0023","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.neurobiolaging.2014.09.007","article-title":"Human secreted tau increases amyloid-beta production","volume":"36","author":"Bright","year":"2015","journal-title":"Neurobiol Aging"},{"issue":"22","key":"10.1016\/j.tjpad.2025.100163_bib0024","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","article-title":"Accelerating Alzheimer's therapeutic development: the past and future of clinical trials","volume":"186","author":"Boxer","year":"2023","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100163_bib0025","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.tjpad.2025.100163_bib0026","article-title":"Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes","author":"Guo","year":"2024","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100163_bib0027","article-title":"Targeting immunometabolic pathways for combination therapy in Alzheimer's disease","volume":"9","author":"Erichsen","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100163_bib0028","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100163_bib0029","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: alzheimer's Association Workgroup","volume":"20","author":"Jr","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100163_bib0030","doi-asserted-by":"crossref","first-page":"418","DOI":"10.14283\/jpad.2023.68","article-title":"Can we use blood biomarkers as entry criteria and for monitoring drug treatment effects in clinical trials? A report from the EU\/US CTAD Task Force","volume":"10","author":"Angioni","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100163_bib0031","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13195-020-00588-4","article-title":"The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease","volume":"12","author":"Colom-Cadena","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100163_bib0032","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of Donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100163_bib0033","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725001086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725001086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:55:15Z","timestamp":1751428515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725001086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2274580725001086"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100163","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU\/US CTAD Task Force","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100163"}}